Clients
Harten Group is one of Europe's leading providers of flexible resourcing solutions to companies in the pharmaceutical and biotech industries, with clients ranging from global players through to smaller start-ups.
With over 2000 highly qualified specialists the company, which has been established for 15 years, delivers flexible resourcing solutions to meet specific needs - mostly in the UK but also in Europe - including help in determining that those requirements are.
Specialist consultants have a wealth of pharma knowledge and experience across a diverse range of areas. On average our consultants have over 15 years of industry experience.
This bank of expertise can be harnessed in many different ways, from the placement of a single consultant on a contract basis, finding a permanent employee or fielding a team of consultants to address a bigger challenge.
Interim Management
Do you need extra resources to cover an unexpected increase in workload? Has a key member of staff fallen ill? Is your company undergoing major changes, resulting in a headcount freeze? Or is there an exciting new business opportunity that needs short-term specialist expertise to bring it to fruition?
Pharmaceutical Consulting
You may need a medical expert report, regulatory document, product acquisition assessment or risk benefit analysis turned around within a tight timescale. Perhaps you want a market entry assessment or Due Diligence report carried out by an independent expert? Or are you anticipating a GCP inspection very soon and concerned that you are not prepared?
Executive Search
With a first-class track record and a sound sectoral reputation, Harten Group has an unrivalled knowledge of the pharmaceutical and biotech industries and an extensive network of over 2000 consultants.
Latest assignments
Interim Compliance Officer
6+ months
Medical Director
18 months
HTA Expert
3 months
Recent projects & updates
A pan-European Pricing and Reimbursement review was required by a US client.
Global pharmaceutical company headquartered in Europe requested a review of all copy approval practices for its European subsidiary.
